HIV mutation literature information.


  Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
 PMID: 21449841       2011       Future microbiology
Abstract: Interestingly, V106M was identified in HIV-1 subtype C as a subtype-specific multi-NNRTI-resistance mutation.


  Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
 PMID: 21487249       2011       AIDS (London, England)
Discussion: However, a previous study suggests that some of those mutations (V106M, Y188C, G190A) may be less likely to persist at high levels in infants after NVP exposure than K103N and Y181C.


  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
 PMID: 21633285       2011       AIDS (London, England)
Result: Other major NNRTI mutations V106M, Y188C and G190A were found in a small proportion of infants under 12 months but were absent in older children.
Result: The G190A and Y188C mutations were each detected in 2 samples and V106I/M in 1 sample.


  High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.
 PMID: 21663632       2011       Journal of the International AIDS Society
Result: V106A/M, K101E and Y188C/L were noted in four, three and two patients, respectively.
Table: V106M


  Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
 PMID: 21694608       2011       Journal of acquired immune deficiency syndromes (1999)
Result: K103N was the most commonly detected in 9 (25%) participants, V106M in 6 (16.7%), and G190S/A +/- Y188C/L in 6 (16.7%).


  Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.
 PMID: 21927716       2011       Journal of AIDS & clinical research
Result: However, the remaining six patients who were re-suppressed had NNRTI DRM, three had K103N, one had K103N and M184V and one had K103N, V106M and M184V (Table 4b).


  Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
 PMID: 22132100       2011       PloS one
Method: RT mutations were iden
Result: Conversely, the use of an efavirenz-based regimen was associated with significantly increased risks of the mutations P225H (PP[OR>1]>99%), V106M (PP[OR>1]>99%), K103N (PP[OR>1]>99%), L100I (PP[OR>1] = 97%), T215Y (PP[OR>1] = 97.5%) and L210W (PP[OR>1]>99%).
Discussion: also found that K103N, V106M and P225H were among the 16 NNRTI mutations preferentially selected by EFV and K101E, Y181C and G190A among the 12 mutations preferentially selected by NVP.


  Correlation between resistance profile and immunosuppression in heavily treated HIV-1 infected Romanian patients.
 PMID: 22180722       2011       Romanian biotechnological letters
Discussion: Group O viruses are resistant to this class of antiretroviral drugs, resistance develops faster in subtype C, due to selection of V106M and resistance to nevirapine after its administration for prevention of mother-to-child transmission in Uganda was more frequently encountered in subtype D than in subtype A.


  HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
 PMID: 23525026       2011       Indian journal of medical sciences
Abstract: RESULTS: Amino acid substitution (K103N and V106MV) at drug resistance positions occurred in two (11%) isolates, conferring high-level resistance to the non-nucleoside reverse-transcriptase inhibitors nevirapine (NVP), efavirenz (EFV), delavirdine (DLV) and notably extensive genetic variations were observed.


  Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa.
 PMID: 19801944       2010       Journal of acquired immune deficiency syndromes (1999)
Abstract: The V106M mutation was more frequent with EFV (30%) than NVP (4%; P = 0.012).



Browser Board

 Co-occurred Entities




   Filtrator